This segment focuses on the research, development, manufacturing, and sales of Active Pharmaceutical Ingredients (APIs) and intermediates. Jiuzhou Pharma utilizes advanced chemical synthesis technologies, including asymmetric catalysis, to produce a wide range of APIs for various therapeutic areas, such as central nervous system disorders, anti-infectives, and cardiovascular diseases. The company's R&D activities include process optimization, new product development, and the implementation of green chemistry principles. Jiuzhou Pharma's manufacturing processes adhere to stringent quality control standards and regulatory requirements, ensuring the production of high-quality APIs. The company's market positioning is as a leading CDMO, providing services to pharmaceutical companies worldwide. Future opportunities include expanding its product portfolio, entering new therapeutic areas, and increasing its global market share. This segment is critical for the company's revenue generation and growth.

Jiuzhou Pharma offers comprehensive Contract Development and Manufacturing Organization (CDMO) services to pharmaceutical companies globally. This segment encompasses the development and manufacturing of APIs and intermediates, as well as formulation development, analytical testing, and clinical trial material supply. The company leverages its expertise in chemical synthesis, process development, and regulatory affairs to provide integrated solutions for its clients. R&D activities include process optimization, scale-up, and technology transfer. Jiuzhou Pharma utilizes advanced technologies and methodologies, including chiral catalysis and continuous manufacturing, to enhance efficiency and quality. The company's CDMO services support a wide range of therapeutic areas, including oncology, cardiovascular diseases, and infectious diseases. The patient impact is realized through the acceleration of drug development timelines and the provision of high-quality APIs for clinical trials and commercial products. Jiuzhou Pharma's market positioning is as a reliable and innovative CDMO partner, offering flexible and customized solutions. Future opportunities include expanding its service offerings, entering new markets, and forming strategic partnerships with pharmaceutical companies. Regulatory and clinical aspects are critical, with the company adhering to GMP standards and supporting clients through the drug development and approval process.